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Background: Salmonella enterica ser. Typhi is the causative
agent of the clinical condition called typhoid fever that results
after an incubation period of 10 to 15 days following infection. The
main line of treatment of typhoid fever includes antibiotics such
as ﬂuoroquinolones and aminoglycosides; however, several stud-
ies have reported decreased susceptibilities of ﬂuoroquinolones
among Salmonella spp isolated from human infections. Thus, this
necessitates the studies to explore alternative or adjunct therapeu-
tic agents.
Methods & Materials: In this study we isolated and screened
the antimicrobial potential of 92 vaginal lactic acid bacteria from
healthy women against S. enterica ser. Typhi MTCC 733 by using
agar gel diffusion assay. Further, the susceptibility of S. enterica to
various antibiotics and the synergistic activity of the culture super-
natant (CS) of the isolate 12a alongwith antibioticswasdetermined
by using Kirby Bauer disk diffusion and chequerboard titration
methods, respectively.
Results: The isolate no. 12a, identiﬁed as Enterococcus spp. by
using physico-chemical characterisation showed broad spectrum
antimicrobial activity against many Gram-negative pathogens
including S. enterica MTCC733. The antimicrobial activity of the CS
of 12awasproteinaceous innature and lost its activity on treatment
with pepsin, proteinase K and papain. The minimum inhibitory
concentration of the CS was 2133 AU/ml and was stable over a
wide pH range of 3-11. Further, the antimicrobial activity of the
CS was lost at 100◦C; 1 hr treatment. The susceptibility of S. enter-
ica to various antibiotics was determined and it showed reduced
susceptibilities to many ﬂuoroquinolones and aminoglycosides.
Chequerboard titration assay showed that CS of 12a synergised
antimicrobial activities of the antibiotics belonging to the classes
ﬂuoroquinolones, aminoglycosides and -lactam against S. enter-
ica.
Conclusion: In conclusion, the study indicates the potential of
the probiotic strains of enterococci as adjunct therapeutic agent
against resistant forms of S. enterica.
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Background: Inﬂuenza virus is a common human pathogen
that has caused serious respiratory illness and death over the past
century. It always had potential to cause widespread pandemics
whenever a new type of Inﬂuenza strain appeared in the human
population and then spread easily from person to person.Although
the treatment of inﬂuenza produces rapid suppression of H1N1
inﬂuenza A virus infection but this effect is not often sustainable
due to theemergenceof drug-resistantH1N1strains .Therefore, it is
important to develop new antiviral strategies to combat wild-type
andmutantH1N1 inﬂuenza A virus infections. Therefore nanotech-
nology based antiviral therapy has been developed, modiﬁcations
of existing antiviral compounds and development of novel antiviral
iron oxide is a prime area of research
Methods & Materials: Glycine coated iron oxide nanoparti-
cles with particle size in the range of 10-15 nm anti-inﬂuenza
activity was elucidated (in vitro and in vivo) utilizing pandemic
inﬂuenza strain A/H1N1/Eastern India/66/pdm09 (H1N1-pdm09).
Anti-inﬂuenza activity was measured by plaque inhibition and
quantifying viral transcripts using quantitative real-time PCR fol-
lowing treatment with Iron oxide nanoparticles in a dose- and
time-dependent manner Cell viability of Iron oxide on MA104 cells
was assessed by MTT assay the antiviral activity of the iron oxide
nanoparticles was evaluated by comparing the TD50 ratio of viral
suspensions treated with the composites to untreated suspensions
Results: 50% cell viability (TD50) was observed at 4.25 pg±2pg
of Iron oxide nanoparticles during in vitro study. The percentage
of plaque inhibition determined for each drug concentration, the
IC50 (50% virus reduction) of H1N1-pdm09 strain (0.5 moi) in vitro
in MA104 cells by the pfu method was observed at 01pg after 72 h.
The antiviral activity determined by change in viral RNA transcripts
within 24 h of virus infection by RT-PCR, 08 fold reductions in virus
found when treated with Iron oxide nanoparticles.
